Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
REReplimune Group, Inc. logo

Replimune Group, Inc. (REPL)

NASDAQ Global Select · Currency in USD
$11.46 ▼ -0.53 (-4.42%)
At close: Oct 23, 4:00 PM ET. Market closed.
$11.46 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$11.99
Open
$11.92
Day's Range
$11.44 – $12.00
52 Week Range
$1.50 – $16.33
Volume
1,904,923
Avg. Volume
3,734,084
Market Cap
$1.08B
Beta (5Y Monthly)
0.94
PE Ratio (TTM)
--
EPS (TTM)
-$3.07
Earnings Date
Oct 28, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$18.67

Profile: Replimune Group, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
465
CEO
Sushil Patel

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1.

Earnings

Next report: Wed, Oct 28, 2026
EPS estimate -$0.78 · Revenue est. $1.00M
DateEst.Actual
Aug 14, 2026-$0.69-$0.72Miss
Jun 29, 2026-$0.73-$0.76Miss
Feb 3, 2026-$0.77-$0.77Miss
Nov 6, 2025-$0.87-$0.90Miss
Aug 7, 2025-$0.83-$0.95Miss
May 22, 2025-$0.75-$0.82Miss

Analyst view

Consensus price target
$18.67 ▲ +62.9%
Range $17.00 – $20.00
Rating: Buy
Buy 73% · Hold 20% · Sell 7%

Get free alerts on REPL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.